Merck
CN

1.10317

Millipore

Fractogel® EMD BioSEC (S)

Sign Into View Organizational & Contract Pricing

Synonym(s):
Fractogel® EMD BioSEC (S)

ligand

(Modified pore structure)

Quality Level

description

for size exclusion chromatography (SEC), suspension in 20% ethanol and 150 mM NaCl (20-40 µm)

product line

Fractogel®

parameter

100 cm/hr max. flow rate
8 bar pressure

matrix active group

Methacrylate

mean particle size

20-40 μm

transition temp

flash point 35 °C (calculated)

density

1.43 g/cm3 at 20 °C

application(s)

viral therapy

separation technique

size exclusion (SEC)

storage temp.

2-30°C

General description

Size exclusion chromatography for separation of proteins in the range between 5 kDa and 1000 kDa

Features and Benefits

Fractogel® EMD BioSEC (S) enables users to:

  • Effectively remove dimer and high molecular weight aggregates and complete an efficient polishing of blood plasma factors
  • Determine apparent molecular weights of proteins
  • Move predictably and efficiently from bench scale to manufacturing scale processing
  • Create a robust, consistent, and transferable process

Packaging

Plastic bottle

Analysis Note

Appearance: Milky turbid suspension,free from impurities(foreign particles)
Microscopic evaluation: Uniform sphericalparticles, noagglomerates, nofines
Extractable matter (water): ≤ 0.03 %
Cerium: ≤ 1 µg/g
Pressure drop(column: ID=1.6 cm, L=10 cm at 5 ml/min): ≤ 5.0 bar
Particle size (d10): 20 - 28 µm
Particle size (d50): 24 - 34 µm
Particle size (d90): 28 - 38 µm
Colony forming units (TAMC + TYMC): ≤ 100 CFU/ml
Endotoxins: ≤ 1.00 EU/ml
Function test (b:a): ≤ 0.7
function test (c:d): ≤ 0.05
Functional Test: Separation of bovine serum albumin, ovalbumin and cytochrom C

Legal Information

FRACTOGEL is a registered trademark of Merck KGaA, Darmstadt, Germany

Pictograms

Flame

Signal Word

Warning

Hazard Statements

Hazard Classifications

Flam. Liq. 3

Storage Class Code

3 - Flammable liquids

WGK

WGK 3

Flash Point(F)

95.0 °F

Flash Point(C)

35 °C


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Documents related to the products that you have purchased in the past have been gathered in the Document Library for your convenience.

Visit the Document Library

Difficulty Finding Your Product Or Lot/Batch Number?

Product numbers are combined with Pack Sizes/Quantity when displayed on the website (example: T1503-25G). Please make sure you enter ONLY the product number in the Product Number field (example: T1503).

Example:

T1503
Product Number
-
25G
Pack Size/Quantity

Additional examples:

705578-5MG-PW

PL860-CGA/SHF-1EA

MMYOMAG-74K-13

1000309185

enter as 1.000309185)

Having trouble? Feel free to contact Technical Service for assistance.

Lot and Batch Numbers can be found on a product's label following the words 'Lot' or 'Batch'.

Aldrich Products

  • For a lot number such as TO09019TO, enter it as 09019TO (without the first two letters 'TO').

  • For a lot number with a filling-code such as 05427ES-021, enter it as 05427ES (without the filling-code '-021').

  • For a lot number with a filling-code such as STBB0728K9, enter it as STBB0728 without the filling-code 'K9'.

Not Finding What You Are Looking For?

In some cases, a COA may not be available online. If your search was unable to find the COA you can request one.

Request COA

Articles

Influenza vaccines are commonly made using egg-based and cell-based manufacturing strategies. Find step-by-step information on the manufacturing process for each method.

A custom-designed cost model is used to explore the economics of vaccine manufacturing across several different modalities including mRNA. The model enables greater process understanding, simulates bottlenecks, and helps to optimize production efficiency.

Learn more one the attenuated viral vaccines manufacturing process: cell culture, clarification, nuclease treatment, chromatography, and sterile filtration.

This technical article breaks down the steps of upstream and downstream bioprocessing and formulation of virus-like particle vaccines.

Related Content

This technical article breaks down the adenovirus vaccine manufacturing process and provides a case study on developing an accelerated and cost-effective single-use adenoviral vector vaccine.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service